Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gri Bio Inc (GRI)

Gri Bio Inc (GRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,454
  • Shares Outstanding, K 1,445
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,960 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta -1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -19.89
  • Number of Estimates 1
  • High Estimate -19.89
  • Low Estimate -19.89
  • Prior Year -162.46
  • Growth Rate Est. (year over year) +87.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.19 +9.13%
on 02/05/26
7.56 -68.39%
on 01/14/26
-3.91 (-62.06%)
since 01/09/26
3-Month
2.19 +9.13%
on 02/05/26
64.12 -96.27%
on 11/24/25
-49.41 (-95.39%)
since 11/11/25
52-Week
2.19 +9.13%
on 02/05/26
311.36 -99.23%
on 04/01/25
-233.28 (-98.99%)
since 02/11/25

Most Recent Stories

More News
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

Register for the two-day virtual event here

AKTX : 0.2456 (+1.45%)
AIM : 0.8437 (-13.51%)
DCOY : 0.7260 (-2.95%)
BULL : 6.24 (-6.02%)
GRI : 2.39 (unch)
MBRX : 4.18 (+0.97%)
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

–  Live video webcast on Wednesday, February 11 th at 1:00 PM EST  LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”),...

GRI : 2.39 (unch)
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026  Balance sheet strengthened to fund operations...

GRI : 2.39 (unch)
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...

GRI : 2.39 (unch)
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio,...

GRI : 2.39 (unch)
GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...

GRI : 2.39 (unch)
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE)...

GRI : 2.39 (unch)
GRI Bio Announces Closing of $8.0 Million Public Offering

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”)...

GRI : 2.39 (unch)
GRI Bio Announces Pricing of $8,000,000 Million Public Offering

LA JOLLA, CA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”)...

GRI : 2.39 (unch)
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with...

GRI : 2.39 (unch)

Business Summary

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

See More

Key Turning Points

3rd Resistance Point 2.65
2nd Resistance Point 2.56
1st Resistance Point 2.48
Last Price 2.39
1st Support Level 2.30
2nd Support Level 2.22
3rd Support Level 2.13

See More

52-Week High 311.36
Fibonacci 61.8% 193.26
Fibonacci 50% 156.77
Fibonacci 38.2% 120.29
Last Price 2.39
52-Week Low 2.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar